Skip to main content
SIGA
NASDAQ Life Sciences

SIGA Technologies Amends Proxy to Clarify Equity Plan Terms, Removes Director Compensation Cap

Analysis by Arik Shkolnikov
Sentiment info
Negative
Importance info
7
Price
$4.8
Mkt Cap
$343.893M
52W Low
$4.29
52W High
$9.62
Market data snapshot near publication time

summarizeSummary

SIGA Technologies filed a supplement to its definitive proxy statement, clarifying terms for its proposed 6.5 million share increase to the 2010 Stock Incentive Plan, including removing a non-employee director compensation cap and specifying employee share limits.


check_boxKey Events

  • Proxy Statement Supplement Filed

    SIGA Technologies filed a supplement to its definitive proxy statement, originally filed on April 28, 2026, for the upcoming Annual Meeting of Stockholders on June 9, 2026.

  • Equity Plan Amendment Clarified

    The supplement amends and restates Proposal 4, which seeks stockholder approval to increase the shares available under the 2010 Stock Incentive Plan by 6,500,000 shares.

  • Director Compensation Cap Removed

    An erroneously included cap on the value of equity awards and cash compensation for non-employee directors has been removed from the plan summary.

  • Employee Share Limit Specified

    The 1,000,000-share limit for individual awards under the plan is clarified to apply only to Company employees.


auto_awesomeAnalysis

This DEFA14A provides important clarifications to the previously filed definitive proxy statement regarding the proposed increase of 6.5 million shares to the 2010 Stock Incentive Plan. The removal of the non-employee director compensation cap and the clarification that the 1,000,000-share limit applies only to employees are material details for shareholders to consider ahead of the June 9, 2026, Annual Meeting. If approved, the plan would increase the total shares available for issuance to 15,000,000, representing a potential dilution of 12.07% on a fully diluted basis, which is substantial. This move is aimed at retaining and attracting key talent, but the potential dilution and changes to director compensation terms warrant close attention from investors.

At the time of this filing, SIGA was trading at $4.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $343.9M. The 52-week trading range was $4.29 to $9.62. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed SIGA - Latest Insights

SIGA
May 08, 2026, 4:06 PM EDT
Source: Wiseek News
Importance Score:
8
SIGA
May 08, 2026, 4:01 PM EDT
Filing Type: DEFA14A
Importance Score:
7
SIGA
May 07, 2026, 4:48 PM EDT
Filing Type: 10-Q
Importance Score:
7
SIGA
May 07, 2026, 4:08 PM EDT
Filing Type: 8-K
Importance Score:
7
SIGA
May 07, 2026, 4:07 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
SIGA
Apr 28, 2026, 4:02 PM EDT
Filing Type: DEF 14A
Importance Score:
7
SIGA
Mar 26, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
9
SIGA
Mar 26, 2026, 4:01 PM EDT
Source: Dow Jones Newswires
Importance Score:
9
SIGA
Mar 11, 2026, 4:04 PM EDT
Source: Wiseek News
Importance Score:
7
SIGA
Mar 10, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
7